摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-amino-5-chloro-N-(1-(4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)butyl)piperidin-4-ylmethyl)-2-methoxybenzamide | 173340-04-0

中文名称
——
中文别名
——
英文名称
4-amino-5-chloro-N-(1-(4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)butyl)piperidin-4-ylmethyl)-2-methoxybenzamide
英文别名
4-amino-5-chloro-N-(1-(4-(2,3-dihydro-1,3-dioxo-1 H-isoindol-2-yl)butyl)piperidin-4-ylmethyl)-2-methoxybenzamide;4-amino-5-chloro-N-[[1-[4-(1,3-dioxoisoindol-2-yl)butyl]piperidin-4-yl]methyl]-2-methoxybenzamide
4-amino-5-chloro-N-(1-(4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)butyl)piperidin-4-ylmethyl)-2-methoxybenzamide化学式
CAS
173340-04-0
化学式
C26H31ClN4O4
mdl
——
分子量
499.01
InChiKey
IHSWFUOEZOCVDU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    656.9±55.0 °C(Predicted)
  • 密度:
    1.277±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    35
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    105
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-amino-5-chloro-N-(1-(4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)butyl)piperidin-4-ylmethyl)-2-methoxybenzamide一水合肼 作用下, 以 乙醇 为溶剂, 生成 4-amino-N-(1-(4-aminobutyl)piperidin-4-ylmethyl)-5-chloro-2-methoxybenzamide
    参考文献:
    名称:
    Benzoic acid compounds and use thereof as medicaments
    摘要:
    苯甲酸化合物的化学式为##STR1##,其中每个符号如规范中定义,其光学异构体及其药用可接受盐;包括该化合物和药用可接受添加剂的药物组合物;以及将该化合物作为活性成分的5-羟色胺4受体激动剂、胃肠促动力剂和用于各种胃肠疾病的治疗剂。本发明的化合物具有对5-羟色胺4受体的高度和选择性亲和力,并显示出激动效应。因此,它们可用于预防和治疗各种胃肠疾病、中枢神经障碍、心脏功能障碍、泌尿系统疾病等,同时还可用作提高疼痛阈值的镇痛用途的有用抗痛觉剂。
    公开号:
    US05864039A1
  • 作为产物:
    参考文献:
    名称:
    Design and synthesis of orally active benzamide derivatives as potent serotonin 4 receptor agonist
    摘要:
    A series of 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamide derivatives bearing an aralkylamino, alkylamino, benzoyl or phenylsulfonyl group at its side chain part at the I-position on the piperidine ring was synthesized. They were evaluated for serotonin 4 (5-HT4) receptor agonist activity by testing their ability to contract the isolated guinea-pig ascending colon. 4-Amino-5-chloro-2-methoxy-N-[1-[5-(1-methylindol-3-ylcarbonylamino)pentyl]piperidin-4-ylmethyl]benzamide (1a, Y-34959) and its related compounds possessed favorable pharmacological profiles for gastrointestinal motility. Unfortunately, the compound 1a showed low bioavailability when given orally presumably due to its poor intestinal absorption rate. Replacement of the 1-methylindol-3-yl carbonylamino moiety of 1a with an aralkylamino (or alkylamino) group did not improve the intestinal absorption rate. Replacement of the 1-methylindol-3-ylcarbonylamino moiety with a benzoyl or phenylsulfonyl group increased the intestinal absorption rate compared with 1a. These compounds revealed good pharmacological profiles for gastrointestinal motility and were superior to 1a in oral bioavailability. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(03)00412-7
点击查看最新优质反应信息

文献信息

  • Benzoic acid compounds and use thereof as medicaments
    申请人:Yoshitomi Pharmaceutical Industries, Ltd.
    公开号:US05864039A1
    公开(公告)日:1999-01-26
    Benzoic acid compounds of the formula ##STR1## wherein each symbol is as defined in the specification, optical isomers thereof and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising this compound and pharmaceutically acceptable additive; and serotonin 4 receptor agonists, gastrointestinal prokinetic agents and therapeutic agents for various gastrointestinal diseases, which comprise this compound as active ingredient. The compounds of the present invention have high and selective affinity for serotonin 4 receptor, and show agonistic effects thereon. Accordingly, they are useful medications for the prophylaxis and treatment of various gastrointestinal diseases, central nervous disorders, cardiac function disorders, urinary diseases, and the like, as well as useful anti-nociceptors for analgesic use which increase threshold of pain.
    苯甲酸化合物的化学式为##STR1##,其中每个符号如规范中定义,其光学异构体及其药用可接受盐;包括该化合物和药用可接受添加剂的药物组合物;以及将该化合物作为活性成分的5-羟色胺4受体激动剂、胃肠促动力剂和用于各种胃肠疾病的治疗剂。本发明的化合物具有对5-羟色胺4受体的高度和选择性亲和力,并显示出激动效应。因此,它们可用于预防和治疗各种胃肠疾病、中枢神经障碍、心脏功能障碍、泌尿系统疾病等,同时还可用作提高疼痛阈值的镇痛用途的有用抗痛觉剂。
  • BENZOIC ACID COMPOUND AND USE THEREOF AS MEDICINE
    申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
    公开号:EP0774460A1
    公开(公告)日:1997-05-21
    Benzoic acid compounds of the formula wherein each symbol is as defined in the specification, optical isomers thereof and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising this compound and pharmaceutically acceptable additive; and serotonin 4 receptor agonists, gastrointestinal prokinetic agents and therapeutic agents for various gastrointestinal diseases, which comprise this compound as active ingredient. The compounds of the present invention selectively activate serotonin 4 receptor, and are useful medications for the prophylaxis and treatment of various gastrointestinal diseases (e.g., delayed gastric emptying, indigestion, meteorism, reflux esophagitis, abdominal indefinite complaint, intestinal pseudoileus, constipation, acute or chronic gastritis, gastric or duodenal ulcer, Crohn's disease, non-ulcer dyspepsia, ulcerative colitis, postgastrectomy syndrome, postoperative digestive function failure, gastrointestinal injury due to gastric neurosis, gastroptosis, diabetes, etc., and irritable bowel syndrome), central nervous disorders (e.g., schizophrenia, depression, anxiety, disturbance of memory and dementia), cardiac function disorders (e.g., cardiac failure and myocardial ischemia), urinary diseases (e.g., dysuria caused by urinary obstruction, ureterolith or prostatomegaly) and the like.
    式中的苯甲酸化合物 其中各符号如说明书中所定义,其光学异构体及其药学上可接受的盐;由该化合物和药学上可接受的添加剂组成的药物组合物;以及由该化合物作为活性成分的5-羟色胺4受体激动剂、胃肠促动力药和各种胃肠道疾病的治疗剂。 本发明的化合物可选择性地激活 5-羟色胺 4 受体,是预防和治疗各种胃肠道疾病(如胃排空延迟、消化不良等)的有效药物、胃排空延迟、消化不良、陨石症、反流性食管炎、腹部不定时主诉、肠假痔、便秘、急性或慢性胃炎、胃或十二指肠溃疡、克罗恩病、非溃疡性消化不良、溃疡性结肠炎、胃切除术后综合征、术后消化功能衰竭、胃神经官能症引起的胃肠道损伤、胃下垂、糖尿病等)、肠易激综合征(肠易激综合征)、胃溃疡、胃炎、胃溃疡等)、和肠易激综合征引起的胃肠道损伤)、中枢神经紊乱(如精神分裂症、抑郁症、焦虑症、记忆障碍和痴呆症)、心脏功能紊乱(如心力衰竭和心肌缺血)、泌尿系统疾病(如尿路梗阻、输尿管结石或前列腺肥大引起的排尿困难)等。
  • BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF
    申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
    公开号:EP0873990A1
    公开(公告)日:1998-10-28
    A benzoic acid compound of the formula wherein each symbol is as defined in the specification, an optical isomer thereof and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising this compound and a pharmaceutically acceptable additive, a serotonin 4 receptor agonist comprising this compound as an active ingredient, a gastrointestinal prokinetic agent and a therapeutic agent for gastrointestinal diseases. The compound of the present invention shows selective and high affinity for serotonin 4 receptors, activates same, is useful as a pharmaceutical agent for the prophylaxis and treatment of gastrointestinal diseases (e.g., reflux esophagitis; gastroesophageal reflux such as that accompanying cystic fibrosis; Barrett syndrome; intestinal pseudoileus; acute or chronic gastritis; gastric or duodenal ulcer; Crohn's disease; non-ulcer dyspepsia; ulcerative colitis; postgastrectomy syndrome; postoperative digestive function failure; delayed gastric emptying caused by gastric neurosis, gastroptosis, diabetes, and the like; gastrointestinal disorders such as indigestion, meteorism, abdominal indefinite complaint, and the like; constipation such as atonic constipation, chronic constipation, and that caused by spinal cord injury, pelvic diaphragm failure and the like; and irritable bowel syndrome), central nervous disorders (e.g., schizophrenia, depression, anxiety, disturbance of memory and dementia), cardiac function disorders (e.g., cardiac failure and myocardial ischemia), urinary diseases (e.g., dysuria caused by urinary obstruction, ureterolith, prostatomegaly, spinal cord injury, pelvic diaphragm failure, etc.), and shows superior absorption.
    式中的苯甲酸化合物 其中各符号如说明书中所定义,其光学异构体及其药学上可接受的盐。由该化合物和药学上可接受的添加剂组成的药物组合物、以该化合物为活性成分的血清素 4 受体激动剂、胃肠促动力药和胃肠疾病治疗剂。 本发明的化合物对 5-羟色胺 4 受体具有选择性和高亲和力,能激活 5-羟色胺 4 受体,可用作预防和治疗胃肠道疾病(如反流性食管炎;反流性食管炎;反流性食管炎;反流性食管炎;反流性食管炎;反流性食管炎;反流性食管炎)的药物、反流性食管炎;胃食管反流,如伴随囊性纤维化的胃食管反流;巴雷特综合征;肠道假膜;急性或慢性胃炎;胃或十二指肠溃疡;克罗恩病;非溃疡性消化不良;溃疡性结肠炎;胃切除术后综合征;术后消化功能衰竭;胃神经官能症、胃下垂、糖尿病等引起的胃排空延迟;消化不良、陨石症、腹部不适等胃肠道疾病;失张性便秘、慢性便秘、脊髓损伤引起的便秘、骨盆膈肌功能衰竭等便秘;肠易激综合征)、中枢神经紊乱(如溃疡性结肠炎g.,精神分裂症、抑郁症、焦虑症、记忆障碍和痴呆症)、心脏功能紊乱(如心力衰竭和心肌缺血)、泌尿系统疾病(如尿路梗阻、输尿管结石、前列腺肥大、脊髓损伤、盆腔膈肌衰竭等引起的排尿困难),并显示出良好的吸收性。
  • EP873990
    申请人:——
    公开号:——
    公开(公告)日:——
  • US5864039A
    申请人:——
    公开号:US5864039A
    公开(公告)日:1999-01-26
查看更多

同类化合物

(1Z,3Z)-1,3-双[[((4S)-4,5-二氢-4-苯基-2-恶唑基]亚甲基]-2,3-二氢-5,6-二甲基-1H-异吲哚 鲁拉西酮杂质33 鲁拉西酮杂质07 马吲哚 颜料黄110 顺式-六氢异吲哚盐酸盐 顺式-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]-N-乙基-1-苯基环丙烷甲酰胺 顺-N-(4-氯丁烯基)邻苯二甲酰亚胺 降莰烷-2,3-二甲酰亚胺 降冰片烯-2,3-二羧基亚胺基对硝基苄基碳酸酯 降冰片烯-2,3-二羧基亚胺基叔丁基碳酸酯 阿胍诺定 阿普斯特降解杂质 阿普斯特杂质29 阿普斯特杂质27 阿普斯特杂质26 阿普斯特杂质 阿普斯特 防焦剂MTP 铝酞菁 铁(II)2,9,16,23-四氨基酞菁 酞酰亚胺-15N钾盐 酞菁锡 酞菁二氯化硅 酞菁 单氯化镓(III) 盐 酞美普林 邻苯二甲酸亚胺 邻苯二甲酰基氨氯地平 邻苯二甲酰亚胺,N-((吗啉)甲基) 邻苯二甲酰亚胺阴离子 邻苯二甲酰亚胺钾盐 邻苯二甲酰亚胺钠盐 邻苯二甲酰亚胺观盐 邻苯二亚胺甲基磷酸二乙酯 那伏莫德 过氧化氢,2,5-二氢-5-苯基-3H-咪唑并[2,1-a]异吲哚-5-基 达格吡酮 诺非卡尼 螺[环丙烷-1,1'-异二氢吲哚]-3'-酮 螺[异吲哚啉-1,4'-哌啶]-3-酮盐酸盐 葡聚糖凝胶G-25 苹果酸钠 苯酚,4-溴-3-[(1-甲基肼基)甲基]-,1-苯磺酸酯 苯胺,4-乙基-N-羟基-N-亚硝基- 苯基甲基2-脱氧-2-(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)-3-O-(苯基甲基)-4,6-O-[(R)-苯基亚甲基]-BETA-D-吡喃葡萄糖苷 苯二酰亚氨乙醛二乙基乙缩醛 苯二甲酰亚氨基乙醛 苯二(甲)酰亚氨基甲基磷酸酯 膦酸,[[2-(1,3-二氢-1,3-二羰基-2H-异吲哚-2-基)苯基]甲基]-,二乙基酯 胺菊酯